Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XGN
SellHot AirExagen Inc. · Healthcare · United States · $179M · Avg Vol: $3M/d
28
StockRankGet insider-trade alerts
Q
35
V
26
M
55
P/E (TTM)
—
ROE
-113.8%
D/E
2.3x
Dividend %
—
COMPANY DESCRIPTION
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.6M | 52.5M | 55.6M | 66.6M | 13.5% | 71.1M | 73.9M | 81.5M | 10.6% |
| EPS | -2.77 | -1.34 | -0.83 | -0.93 | — | -0.82 | -0.62 | -0.47 | — |
| Shares | 16.5M | 17.0M | 17.6M | 22.9M | +38.4% | 24.2M | — | — | — |
| Debt | 35.2M | 23.2M | 23.2M | 25.7M | -9.9% | 27.7M | — | — | — |
| Equity | 42.5M | 22.7M | 9.5M | 17.4M | -25.7% | — | — | — | — |
| Op CF | -32.1M | -14.5M | -13.3M | -13.6M | — | -6.5M | — | — | — |
| Inv CF | -4.3M | -0.8M | -0.5M | -0.6M | — | — | — | — | — |
| Fin CF | -0.5M | -10.6M | -0.7M | 24.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+49.3%
SMA 50SMA 200
Close
$6.97
RSI (14)
31.3
52W High
$12.23
From 52W High
0.6%
SCORE BREAKDOWN
Quality
35
ROIC
-31.4%24.0
ROE
-113.8%8.1
GP/Assets
71.9%94.8
Op. Margin
-8.6%27.9
FCF/Assets
-13.1%26.5
Piotroski
316.0
Int. Cover
-2.7x30.4
D/E Ratio
2.26x4.5
Current Ratio
3.19x57.8
Value
26
P/E (TTM)
—N/A
EV/EBITDA
-17.3x25.0
P/FCF
—N/A
P/B
15.0x7.7
P/S
2.6x61.4
Div Yield
—N/A
Momentum
55
52W High %
57%32.1
RS 6M
111%97.8
SMA 50/200
1.25x90.8
EPS Rev 4W
-2.3%19.5
EPS Rev 12W
—N/A
EPS Improve
+46%52.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$179M
P/E (Forward)
-17.2x
Gross Margin
58.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XGN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XGN | Exagen Inc.(you) | $179M | 28 | Sell |
| BDSX | Biodesix, Inc. | $283M | 29 | Sell |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
| 950200.KQ | Psomagen, Inc. | $50M | 24 | Sell |
| IMDX | Insight Molecular Diagnostics Inc. | $135M | 3 | Strong Sell |
| 950130.KQ | Access Bio, Inc. | $65M | 13 | Strong Sell |
| FLGT | Fulgent Genetics, Inc. | $540M | 45 | Hold |
| PRPO | Precipio, Inc. | $52M | 47 | Hold |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
| OPK | OPKO Health, Inc. | $1.1B | 38 | Hold |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%